Shares of GRI Bio Inc. (GRI) are up over 180% at $1.68 in premarket trading Monday as the company gears up for a clinical trial event related to its lead drug candidate this quarter.
The lead asset, GRI-0621, being developed for the treatment of idiopathic pulmonary fibrosis (IPF), is a small molecule RAR-ß? dual agonist that inhibits the activity of human iNKT cells. In multiple animal models, iNKT inhibition has demonstrated fibrosis resolution, according to the company.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.